ViaCyte, Inc. (Formerly Known as Novocell, Inc.) To Present At JDRF TypeOneNation Research Summit

SAN DIEGO and BETHESDA, Md., March 3, 2015 /PRNewswire/-- ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Eugene Brandon, Director of Strategic Relations and Project Management, at the JDRF TypeOneNation Summit.  The annual summit showcases the latest in type 1 diabetes management technology and treatments.

ViaCyte logo.

Details of the presentation are as follows:


Developing an Encapsulated Cell Therapy for Diabetes: The ViaCyte Story


Saturday, March 7th at 10:50 am EST


Bethesda North Marriott Hotel and Conference Center, Bethesda, Md.

Dr. Brandon will review recent progress with the company's VC-01 product candidate for the treatment of type 1 diabetes, which recently entered the clinical phase of development.  A Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type 1, was launched in September 2014, and the first implant was announced in October 2014.

For more information about the JDRF TypeOneNation Summit, please visit:

About ViaCyte
ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.  ViaCyte is conducting a Phase 1/2 clinical trial of the Company's lead product candidate VC-01 in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function.  ViaCyte's VC-01 combination product is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells.  These progenitor cells are implanted in a durable and retrievable encapsulation device.  Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels.  The VC-01 product is being developed as a potential long-term diabetes treatment without immune suppression, and without risk of hypoglycemia or other diabetes-related complications. 

ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF. 

For more information please visit  Connect with ViaCyte here: and

Investor Contact: Lisa Wilson, In-Site Communications, Inc., +1.212.452.2793,




To view the original version on PR Newswire, visit:


Help employers find you! Check out all the jobs and post your resume.

Back to news